reviewed april 2026|next review october 2026|88 physicians psi has verified|1210 published studies
Klotho Peptide
Klotho is a naturally occurring (the body's own) anti-aging protein whose peptide fragments are being studied for cognitive enhancement and organ protection, with klotho-overexpressing mice living 20-30% longer, a single klotho fragment injection improving cognition in aged mice and aged rhesus monkeys, and human observational data linking higher klotho levels to better cognitive function and kidney health.
Evidence landscape: 1210 published studies
Published studies indexed under this compound. The broader klotho literature exceeds 4,500 papers spanning aging, nephrology, neuroscience, and cardiovascular biology.
- 72 Human
- 94 Animal
- 34 Reviews
- 1010 Other research
Not FDA-approved. No klotho-based therapeutic has entered clinical trials. A klotho fragment improved cognition in aged nonhuman primates (2023 Nature Aging), representing the closest step toward clinical translation. Therapeutic development is in early stages with animal studies only.
Not commercially available as a therapeutic. Klotho is naturally occurring (the body's own), primarily produced by the kidney. Exercise increases klotho levels. Klotho testing is available through specialty longevity laboratories but is not part of standard bloodwork.
Named after the Greek goddess who spins the thread of life. One of the strongest candidates for a genuine anti-aging factor based on genetic evidence: klotho-deficient mice develop a premature aging syndrome, and overexpression extends lifespan by 20-30%. The 2023 nonhuman primate data brought the research closer to potential human application.
PSI Assessment
Mice without klotho age rapidly and die young. Mice with extra klotho live 20-30% longer. A single injection of a klotho protein fragment restored cognitive function in aged mice and, in a pivotal 2023 study, improved working memory in aged rhesus monkeys. Human carriers of a klotho gene variant that produces higher levels perform better on cognitive tests. The evidence builds across species and study types, creating one of the strongest animal research cases in longevity science. The critical gap remains: no human therapeutic trial has been completed.
20-30% lifespan extension in mice. Cognitive enhancement in aged monkeys (2023). Human genetic variant associated with better cognition. No human therapeutic trial completed.
The mechanism operates through multiple pathways. Membrane-bound klotho acts as a co-receptor for FGF23 (fibroblast growth factor 23) in the kidney, regulating phosphate and vitamin D metabolism. Secreted (circulating) klotho acts as a hormone that suppresses insulin/IGF-1 signaling (a validated longevity pathway), inhibits Wnt signaling, reduces TGF-beta-mediated fibrosis, and decreases oxidative stress. In the brain, the KL1 (klotho domain 1) peptide enhances synaptic plasticity by increasing GluN2B-containing NMDA (N-methyl-D-aspartate) receptor abundance in the hippocampus.
What the evidence supports
Klotho deficiency accelerates aging and overexpression extends lifespan by 20-30% in mice. This is one of the most dramatic lifespan results in aging research. A single peripheral injection of a klotho fragment improved cognitive function in aged mice and aged rhesus monkeys (2023 Nature Aging), providing cross-species replication. Human observational studies link higher klotho levels to better cognitive function and slower kidney decline. Over 4,500 published studies establish the biology.
What is not yet established
Whether klotho peptide supplementation produces anti-aging or cognitive benefits in humans. No human therapeutic trial has been completed. Optimal delivery and dosing of klotho fragments. Long-term safety of exogenous klotho. Effects on mineral metabolism from FGF23 pathway modulation.
Research Evidence
The findings below cover the genetic lifespan evidence, the cognitive enhancement data across species, and the human observational associations.
Evidence by condition
Evidence dimensions across klotho research areas. Cognitive aging has the most compelling cross-species data. Longevity has dramatic genetic evidence. Kidney/FGF23 biology has the strongest mechanistic characterization.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cognitive Aging | ||||
| Longevity | ||||
| Kidney/FGF23 | ||||
| Phosphate Metabolism |
Klotho-overexpressing mice live 20-30% longer than controls while suppressing insulin/IGF-1 signaling. Klotho-deficient mice develop a premature aging syndrome including arteriosclerosis, osteoporosis, skin atrophy, and emphysema within weeks of birth.
The lifespan extension and premature aging phenotype are among the most dramatic results in genetic aging research. The insulin/IGF-1 suppression mechanism connects klotho to the established biology of aging conserved from worms to mammals.
A single peripheral injection of a klotho protein fragment improved cognitive function in aged mice, and a 2023 Nature Aging study extended this finding to aged rhesus monkeys. The treated monkeys showed enhanced working memory that persisted for at least two weeks after a single low-dose administration.
The cross-species replication from mice to primates substantially strengthens the translational case. The peripheral-to-central signaling mechanism (the klotho fragment does not need to enter the brain directly) opens practical therapeutic possibilities.
Human carriers of the KL-VS (klotho variant sequence) klotho gene variant have higher circulating klotho levels and perform better on cognitive tests. Prospective cohort studies show that lower plasma klotho concentrations predict faster cognitive decline in older adults.
The human genetic and observational data is consistent with the animal intervention data but cannot prove causation. The question of whether raising klotho levels in humans would improve cognition awaits an interventional clinical trial.
72 Human|94 Animal|34 Reviews
View all 1210 indexed studiesHow Klotho Peptide Works
Klotho works as an anti-aging shield. It protects kidneys, brain, and blood vessels from the damage that accumulates with age. When klotho levels are high, organs stay healthier longer. When they drop (as happens naturally with aging), the aging process accelerates. In the brain, a klotho fragment strengthens the connections between neurons that are needed for memory and learning.
Klotho works as an anti-aging shield. It protects kidneys, brain, and blood vessels from the damage that accumulates with age. When klotho levels are high, organs stay healthier longer. When they drop (as happens naturally with aging), the aging process accelerates.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Klotho exists as membrane-bound (type I transmembrane protein, co-receptor for FGF23 in the kidney) and secreted/cleaved forms. The secreted form acts as a circulating hormone that suppresses insulin/IGF-1 signaling (via inhibition of insulin receptor substrate phosphorylation), inhibits Wnt signaling (direct binding to Wnt ligands), suppresses TGF-beta-mediated fibrosis, and reduces oxidative stress. In the brain, the KL1 domain fragment enhances hippocampal synaptic plasticity by increasing GluN2B-containing NMDA receptor surface expression. Klotho also regulates phosphate homeostasis via FGF23 signaling and modulates calcium/TRPV5 (transient receptor potential vanilloid 5) channel activity in the kidney.
What is Klotho Peptide being studied for?
Researchers are studying Klotho Peptide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Klotho Peptide overall. This means a compound can have human studies for one condition but only animal data for another.
Cognitive Aging
·Animal StudiesA single klotho fragment injection improved cognition in aged mice and aged rhesus monkeys (2023). Human carriers of the KL-VS variant show better cognitive performance. Lower plasma klotho predicts faster cognitive decline in prospective studies.
Limitations: No human therapeutic trial. Whether exogenous klotho peptide can replicate the cognitive effects seen in animals is untested. The human genetic and observational data is consistent but cannot prove causation.
Longevity
·Animal StudiesKlotho overexpression extends mouse lifespan by 20-30%. Klotho deficiency causes premature aging. These are among the most dramatic genetic lifespan results in mammalian research.
Limitations: Mouse overexpression studies cannot be directly translated to human peptide supplementation. The relationship between circulating klotho levels and lifespan in humans is correlative.
Kidney/FGF23
·Human TrialsKlotho is the obligate co-receptor for FGF23 signaling in the kidney. Klotho deficiency accelerates kidney disease progression. Klotho levels serve as a biomarker of kidney health and decline early in chronic kidney disease.
Limitations: Whether klotho supplementation can slow kidney disease in humans is unproven. The kidney is the primary source of klotho, creating a decline cycle in CKD.
Phosphate Metabolism
·Animal StudiesKlotho regulates phosphate homeostasis through FGF23 signaling. Klotho deficiency causes hyperphosphatemia and vascular calcification in animal models (animal research).
Limitations: Therapeutic modulation of klotho must account for effects on mineral metabolism. Phosphate dysregulation is a potential safety consideration for any klotho-based intervention.
Safety and Regulatory Status
FDA Status: Not FDA-approved. No klotho-based therapeutic has entered clinical trials. The 2023 nonhuman primate data represents the most advanced translational milestone.
Availability: Not commercially available as a therapeutic. Klotho testing is available through specialty longevity laboratories. Exercise and kidney health support the body's own klotho production.
Class context: Naturally occurring (the body's own) protein. No safety concerns from normal physiology. Therapeutic klotho administration must account for effects on mineral metabolism (phosphate, calcium, vitamin D) via the FGF23 pathway. This is the primary theoretical safety consideration.
Klotho is naturally occurring (the body's own) with no safety concerns from normal physiology. The primary consideration for therapeutic development is that klotho regulates mineral metabolism through FGF23 signaling. Any klotho-based intervention would need to account for effects on phosphate, calcium, and vitamin D balance.
Questions and Comparisons
Questions the evidence raises for a Klotho Peptide discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The landmark discovery of the klotho gene. Researchers found that mice with a defective klotho gene developed a syndrome that closely mimicked human aging, including shortened lifespan, atherosclerosis, skin atrophy, osteoporosis, and emphysema. Conversely, overexpressing klotho extended lifespan. This paper opened the field of klotho biology and its connection to aging.Kuro-o M et al., 1997 in Nature. View on PubMed
- 2.Demonstrated that overexpression of the klotho gene in mice extended their lifespan by 20-30%. The study showed that circulating klotho protein acts as a hormone that suppresses insulin/IGF-1 signaling, a pathway known to regulate longevity across species. This provided the first mechanistic link between klotho and the established biology of aging.Kurosu H et al., 2005 in Science. View on PubMed
- 3.Demonstrated that elevating klotho levels enhanced cognitive function in both young and aging mice, improving spatial learning and memory. The cognitive enhancement was mediated by increased GluN2B-containing NMDA receptor abundance in the hippocampus, establishing a molecular mechanism linking klotho to brain function. Human carriers of a klotho gene variant (KL-VS) also showed better cognitive performance.Dubal DB et al., 2014 in Cell Rep. View on PubMed
- 4.Demonstrated that a single low-dose injection of klotho protein fragment improved cognitive function in aged rhesus monkeys. The treated animals showed enhanced working memory and executive function that persisted for at least two weeks after a single administration. This study was pivotal because it showed klotho's cognitive benefits extend to primates, bringing the research closer to potential human application.Castner SA et al., 2023 in Nat Aging. View on PubMed
- 5.Showed that a single peripheral injection of a klotho protein fragment improved cognitive function in aged mice and in a mouse model of neurodegeneration. The klotho fragment did not need to enter the brain directly, suggesting a peripheral-to-central signaling mechanism that opens therapeutic possibilities for neurodegenerative conditions.Leon J et al., 2017 in J Neurosci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.